Coccidioidomycosis in Rheumatology Patients
Identifieur interne : 001B71 ( Main/Exploration ); précédent : 001B70; suivant : 001B72Coccidioidomycosis in Rheumatology Patients
Auteurs : Lester E. Mertz [États-Unis] ; Janis E. Blair [États-Unis]Source :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2007-09.
English descriptors
- Teeft :
- Ankylosing spondylitis, Antirheumatic, Arthritis, Arthritis rheum, Azathioprine, Blair, Chronic lung disease, Clinical course, Coccidioidal, Coccidioidomycosis, Coccidioidomycosis diagnosis, Comorbid, Comorbid conditions, Database, Demographic details, Dmards, General population, Health services, Immunosuppressive, Immunosuppressive medications, Incidence rates, Incidence values, Infectious diseases, Inflammatory, Inflammatory arthritis, Infliximab, Infliximab prednisone, Infliximab therapy, Isds, January, June, Mayo clinic, Medication, Mertz, Mertz blair, Methotrexate, Office visits, Patient subgroup, Prednisone, Rheumatic, Rheumatic disease, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatology, Rheumatology practice, Risk factors, Sciences table, Serologic, Study interval, Study period, Symptomatic coccidioidomycosis, Systemic lupus erythematosus, Tnfi, Tnfi therapy, York academy.
Abstract
Abstract: Coccidioidomycosis is a potentially serious fungal infection contracted in endemic areas of the desert southwestern United States. Limited information exists about its incidence and clinical course in patients with rheumatic diseases, who may be at higher risk of symptomatic or disseminated coccidioidomycosis because of either the rheumatic disease itself or its treatment. We analyzed the incidence and risk factors for symptomatic and complicated coccidioidomycosis in our academic rheumatology practice in central Arizona. Between January 1, 2000, and June 30, 2006, coccidioidomycosis was diagnosed in 1.9% of the overall practice and in 3.1–3.6% of patients with rheumatoid arthritis (RA). The annual incidence was 1% in patients recently diagnosed with RA and 2% among patients with recently initiated infliximab treatment. Coccidioidomycosis was identified only in patients with inflammatory rheumatic diseases and extrathoracic dissemination occurred only to joints in two patients. Corticosteroids, immunosuppressive medications, and tumor necrosis factor inhibitors (TNFIs) appeared to be risk factors for symptomatic, but not disseminated coccidioidomycosis.
Url:
DOI: 10.1196/annals.1406.027
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E16
- to stream Istex, to step Curation: 000E16
- to stream Istex, to step Checkpoint: 000A54
- to stream Main, to step Merge: 001B82
- to stream Main, to step Curation: 001B71
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coccidioidomycosis in Rheumatology Patients</title><author><name sortKey="Mertz, Lester E" sort="Mertz, Lester E" uniqKey="Mertz L" first="Lester E." last="Mertz">Lester E. Mertz</name></author><author><name sortKey="Blair, Janis E" sort="Blair, Janis E" uniqKey="Blair J" first="Janis E." last="Blair">Janis E. Blair</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9442AB13A94C161996C68214CF75C1DE6BEE8CF5</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1196/annals.1406.027</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-PGD1RN4P-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000E16</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E16</idno><idno type="wicri:Area/Istex/Curation">000E16</idno><idno type="wicri:Area/Istex/Checkpoint">000A54</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000A54</idno><idno type="wicri:doubleKey">0077-8923:2007:Mertz L:coccidioidomycosis:in:rheumatology</idno><idno type="wicri:Area/Main/Merge">001B82</idno><idno type="wicri:Area/Main/Curation">001B71</idno><idno type="wicri:Area/Main/Exploration">001B71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Coccidioidomycosis in Rheumatology Patients</title><author><name sortKey="Mertz, Lester E" sort="Mertz, Lester E" uniqKey="Mertz L" first="Lester E." last="Mertz">Lester E. Mertz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Blair, Janis E" sort="Blair, Janis E" uniqKey="Blair J" first="Janis E." last="Blair">Janis E. Blair</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Mayo Clinic, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Annals of the New York Academy of Sciences</title><title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title><idno type="ISSN">0077-8923</idno><idno type="eISSN">1749-6632</idno><imprint><biblScope unit="vol">1111</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="343">343</biblScope><biblScope unit="page" to="357">357</biblScope><biblScope unit="page-count">15</biblScope><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2007-09">2007-09</date></imprint><idno type="ISSN">0077-8923</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0077-8923</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Ankylosing spondylitis</term><term>Antirheumatic</term><term>Arthritis</term><term>Arthritis rheum</term><term>Azathioprine</term><term>Blair</term><term>Chronic lung disease</term><term>Clinical course</term><term>Coccidioidal</term><term>Coccidioidomycosis</term><term>Coccidioidomycosis diagnosis</term><term>Comorbid</term><term>Comorbid conditions</term><term>Database</term><term>Demographic details</term><term>Dmards</term><term>General population</term><term>Health services</term><term>Immunosuppressive</term><term>Immunosuppressive medications</term><term>Incidence rates</term><term>Incidence values</term><term>Infectious diseases</term><term>Inflammatory</term><term>Inflammatory arthritis</term><term>Infliximab</term><term>Infliximab prednisone</term><term>Infliximab therapy</term><term>Isds</term><term>January</term><term>June</term><term>Mayo clinic</term><term>Medication</term><term>Mertz</term><term>Mertz blair</term><term>Methotrexate</term><term>Office visits</term><term>Patient subgroup</term><term>Prednisone</term><term>Rheumatic</term><term>Rheumatic disease</term><term>Rheumatic diseases</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Rheumatology practice</term><term>Risk factors</term><term>Sciences table</term><term>Serologic</term><term>Study interval</term><term>Study period</term><term>Symptomatic coccidioidomycosis</term><term>Systemic lupus erythematosus</term><term>Tnfi</term><term>Tnfi therapy</term><term>York academy</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Coccidioidomycosis is a potentially serious fungal infection contracted in endemic areas of the desert southwestern United States. Limited information exists about its incidence and clinical course in patients with rheumatic diseases, who may be at higher risk of symptomatic or disseminated coccidioidomycosis because of either the rheumatic disease itself or its treatment. We analyzed the incidence and risk factors for symptomatic and complicated coccidioidomycosis in our academic rheumatology practice in central Arizona. Between January 1, 2000, and June 30, 2006, coccidioidomycosis was diagnosed in 1.9% of the overall practice and in 3.1–3.6% of patients with rheumatoid arthritis (RA). The annual incidence was 1% in patients recently diagnosed with RA and 2% among patients with recently initiated infliximab treatment. Coccidioidomycosis was identified only in patients with inflammatory rheumatic diseases and extrathoracic dissemination occurred only to joints in two patients. Corticosteroids, immunosuppressive medications, and tumor necrosis factor inhibitors (TNFIs) appeared to be risk factors for symptomatic, but not disseminated coccidioidomycosis.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li></region></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Mertz, Lester E" sort="Mertz, Lester E" uniqKey="Mertz L" first="Lester E." last="Mertz">Lester E. Mertz</name></region><name sortKey="Blair, Janis E" sort="Blair, Janis E" uniqKey="Blair J" first="Janis E." last="Blair">Janis E. Blair</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9442AB13A94C161996C68214CF75C1DE6BEE8CF5
|texte= Coccidioidomycosis in Rheumatology Patients
}}
| This area was generated with Dilib version V0.6.33. |  |